GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Myriad
Who are Myriad's core customers today?
The 2025 expansion of Myriad Genetics' RiskScore to all ancestries marks a shift toward inclusive precision medicine, broadening clinical reach beyond high-risk oncology to population health, prenatal, and psychiatry settings. This change supports diverse patient cohorts and value-based care partnerships.
Myriad’s target market now spans genetic counselors and oncologists, health systems and payers, prenatal clinics, and direct-to-consumer channels—serving an age range from reproductive-age adults to seniors with hereditary risk; geographic reach includes the US, Europe, and expanding global labs.
What is Customer Demographics and Target Market of Myriad Company? Very short: clinicians, health systems, payers, and diverse ancestry patients seeking risk stratification and actionable genomic insights; see Myriad Porter's Five Forces Analysis
Who Are Myriad’s Main Customers?
Primary customer segments for Myriad Company span healthcare providers as decision-makers and patients as end-users, concentrated in Women’s Health, Oncology, and Mental Health, with Women’s Health accounting for approximately 42% of 2025 revenue.
Women’s Health
Targets women aged 25–45 planning or managing pregnancies; Prequel and Foresight drive growth amid delayed childbearing and higher genetic awareness.
Oncology
Focuses on cancer survivors and those with family history, primarily ages 40–75; legacy strength in breast and ovarian testing sustains steady revenue share.
Mental Health
Powered by GeneSight pharmacogenomics, the fastest-growing segment with > 550,000 tests in 2025, targeting patients 18–45 who failed prior medication trials.
Payor & Socioeconomic Profile
Core customers are middle-to-high-income with private insurance or Medicare; 2025 initiatives expanded ancestry-informed models to capture Medicaid and diverse ethnic groups.
Segmentation reflects a B2B2C structure where clinicians and health systems drive adoption, while patient demographics determine volume and growth; see company background in Brief History of Myriad.
Key implications for targeting
Customer demographics and market segmentation indicate priorities for commercialization, payer engagement, and outreach to underserved groups.
- Prioritize obstetric and reproductive clinicians for Women’s Health uptake
- Engage oncology care teams and survivorship programs for consistent referrals
- Scale behavioral health partnerships and primary care for GeneSight access
- Invest in ancestry-informed models to grow Medicaid and diverse-market share
Complete Myriad Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
What Do Myriad’s Customers Want?
Myriad Company customer needs center on clinical utility, speed, price transparency and actionable results; patients seek reduced uncertainty while clinicians demand EMR-integrated, quick-to-interpret reports and lower VUS rates.
Patient priorities
Patients value clear out-of-pocket estimates, rapid turnaround and support resources to interpret results.
Financial transparency
Market research shows 75 percent of patients prefer providers with integrated financial assistance and pre-test cost estimates.
Out-of-pocket outcomes
Myriad’s price-transparency tools ensure the majority of patients pay less than $100 out-of-pocket for testing.
Clinician workflow
Clinicians prioritize EMR integration, fast interpretation and concise, color-coded reports for use during standard visits.
EMR integration
Systems like Epic and Oracle Health account for over 65 percent of Myriad’s order volume, reflecting clinician preference for EMR-connected tests.
Data confidence
Myriad’s proprietary database lowers Variants of Uncertain Significance (VUS) frequency, increasing clinician adoption and trust.
Pharmacogenomics & patient empowerment
Demand for personalized medication drives interest in GeneSight-style services; 24/7 portals and education improve adoption and Net Promoter Scores.
- Patients seek to avoid trial-and-error prescribing through pharmacogenomics
- Support portals and educational content increase perceived value and adherence
- High NPS in pharmacogenomics reflects aspirational and clinical utility
- See further analysis in the Marketing Strategy of Myriad
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Where does Myriad operate?
The United States is the dominant market for Myriad Company, representing about $843 million of the projected $915 million revenue for 2025, with major laboratory hubs in Salt Lake City and South San Francisco and growing digital reach into suburban and rural areas.
Domestic Footprint
Myriad Company’s U.S. presence drives ~92% of 2025 revenue; brand strength is concentrated in metros with academic medical centers and oncology practices.
Laboratory Hubs
Large labs in Salt Lake City and South San Francisco support high-throughput genetic testing and rapid turnaround for clinical partners nationwide.
Rural & Suburban Expansion
Telehealth and digital platforms have expanded access in remote areas, increasing test volume outside core metros and improving geographic customer distribution.
International Model
A hybrid approach uses direct sales and partnerships across Europe, Japan and the Middle East; 2025 Southeast Asia expansion relied on licensing to local labs to limit capex.
Oncology Focus Abroad
Europe and Japan emphasize companion diagnostics integrated with local health systems to navigate reimbursement and socialized medicine.
Pricing & Payer Strategy
In the U.S. the strategy targets favorable coverage with commercial payers such as UnitedHealthcare and Aetna; internationally, offerings are often positioned as premium for self-pay or private hospitals.
Portfolio Prioritization
Recent withdrawals from underperforming direct-to-consumer international segments freed resources to focus on high-margin domestic business and high-growth Asian partnerships.
Market Segmentation
Regional buying power and regulation drive segmentation: commercial-payer-dependent U.S. markets versus self-pay/private hospital channels internationally.
Growth Metrics
Projected 2025 revenue allocation underscores ~92% U.S. concentration, while Southeast Asia licensing aims to capture rising demand from expanding middle-class populations.
Further Reading
See analysis of regional competitors and strategic positioning in Competitors Landscape of Myriad.
Myriad Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
How Does Myriad Win & Keep Customers?
Myriad Company combines a 600+ specialized sales force with AI-enabled digital tools and targeted digital marketing to acquire clinicians and patients, while retention relies on deep EMR integration and cross-selling to drive lifetime value.
Sales force & clinical outreach
A field team of over 600 professionals targets OB/GYNs, oncologists and psychiatrists to generate clinician-initiated orders and maintain referral pipelines.
AI-driven point-of-care alerts
The Myriad Pro portal flags patients meeting genetic screening criteria from EMR pedigrees, increasing appropriate testing capture at the point of care.
Digital & social acquisition
For GeneSight and women’s health, targeted SEM and testimonial-led social campaigns drive patient-initiated conversations and direct-to-clinic demand.
Clinical workflow retention
Once integrated into an EMR, Myriad’s testing suite creates high switching costs; account retention exceeds 95%, per 2025 internal reporting.
The company maximizes customer lifetime value via CRM-tracked cross-selling across life stages, re-engaging patients from prenatal to hereditary cancer and pharmacogenomics; in 2025 about 15% of new volume came from existing patients or relatives. Growth Strategy of Myriad
Cross-sell pathways
CRM journeys enable personalized outreach so prenatal users are later engaged for cancer or pharmacogenomic tests based on lifecycle triggers.
Patient-led pull strategy
SEM and influencer-driven content generate patient inquiries; mental health marketing emphasizes GeneSight’s evidence and testimonials.
Retention metrics
Deep EMR integration delivers sustained revenue per account and an implied high customer lifetime value through repeat testing and family-member referrals.
Target market alignment
Primary customers include OB/GYNs, oncologists, psychiatrists and health systems—aligning Myriad Company customer profile with clinical decision-makers and patient consumers.
Data-driven segmentation
Segmentation uses EMR-derived clinical criteria, purchase history and demographics to prioritize outreach and optimize marketing ROI.
Key performance signals
Leading indicators include portal alert conversion rates, SEM click-to-appointment ratios, and percentage of test volume from repeat or family referrals.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Myriad Company?
- What is Competitive Landscape of Myriad Company?
- What is Growth Strategy and Future Prospects of Myriad Company?
- How Does Myriad Company Work?
- What is Sales and Marketing Strategy of Myriad Company?
- What are Mission Vision & Core Values of Myriad Company?
- Who Owns Myriad Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.